Myasthenia gravis
RSS feedTowards a reassessment of certain contraindications to the use of drugs in autoimmune myasthenia gravis
American researchers have investigated the possible complications associated with the use of several classes of antibiotics known to be harmful to myasthenia gravis patients: data from patients followed between 2002 and 2022 in Cleveland (USA) and taking ciprofloxacin, levofloxacin (both fluoroquinolones) or azithromycin, were analysed retrospectively. The main endpoint was the occurrence of decompensation of … [Read more]
Researchers from the Institute at the 15th MGFA International Conference
Institute researchers at the 15th International MGFA ConferenceInstitute experts presented their work at the 15th International MGFA Conference on myasthenia gravis and associated disorders, held from 13 May to 15 May 2025 in The Hague, Netherlands. Organised by the Myasthenia Gravis Foundation of America (MGFA), this conference brings together neuromuscular researchers and healthcare professionals to … [Read more]
A new murine model of myasthenia gravis that is more effective and better suited to animal welfare
The Myasthenia gravis, etiology, pathophysiology & therapeutical approaches team, led by Rozen Le Panse at the Institute of Myology’s Myology Research Centre, has developed a new experimental murine model of myasthenia gravis (N-EAMG) that is at least as effective as the classic experimental model (C-EAMG) and offers several advantages. N-EAMG: is better suited to animal … [Read more]
Towards a European register of autoimmune myasthenia gravis cases
At a time when innovative therapies are being developed for refractory forms of autoimmune myasthenia gravis, the idea of setting up a European register is gaining ground: to this end, a group of experts comprising 11 neurologists, 4 neuropaediatricians and a physiotherapist was brought together to define the most relevant items for the future register, … [Read more]
Real-life pharmacovigilance identifies unreported side effects of eculizumab and alglucosidase alpha
Two Chinese teams looked at the real-life side-effects of eculizumab in the treatment of myasthenia and alglucosidase alfa in the treatment of Pompe disease. Analysis of data from the FDA’s pharmacovigilance system, FAERS (FDA Adverse Event Reporting System), revealed : 46,316 side-effect reports for eculizumab between 2007 and 2023, grouped under 461 preferred terms; 4,326 … [Read more]
Positive phase III results for nipocalimab in generalised myasthenia gravis
The Vivacity-MG3 phase III trial included 153 adults with generalised myasthenia to evaluate nipocalimab, a monoclonal antibody targeting the neonatal Fc receptor (FcRn). Of all the patients, 88% had anti-RACh autoantibodies, 11% had anti-MuSK autoantibodies and 2% had anti-LRP4 autoantibodies. Patients were randomised into two groups: 77 received nipocalimab and 76 a placebo, every fortnight … [Read more]
A majority of patients with refractory myasthenia gravis experience durable remission after autologous haematopoietic stem cell transplantation
Following an initial report of three cases in 2022, a Canadian team has published the results of a retrospective study of 21 patients with severe and refractory Myasthenia Gravis with anti-MusK or anti-RACh, treated by autologous haematopoietic stem cell transplantation 1.9 to 21.8 years after diagnosis. Out of 18 evaluable patients : 16 achieved and … [Read more]
Searching for markers of myasthenia gravis in French National Health Insurance data
Over the period 2013-2020, 14,459 people in France received reimbursements for care related to autoimmune myasthenia gravis, including 6,354 for the first time. Of these, : 34.6% were hospitalised at least once in intensive care, 2,817 patients received IVIG and 432 received plasma exchange, these events, which indicate poor control of the disease, mainly occurred … [Read more]
An algorithm to assist diagnostic for seronegative autoimmune myasthenia gravis
At the 275th workshop of the European Neuromuscular Centre (ENMC), held in February 2024 in the Netherlands, experts and patient representatives met to review the diagnosis and management of seronegative autoimmune myasthenia gravis in the light of the latest advances. They concluded that : seronegative autoimmune myasthenia (undetectable autoantibodies) affects 10 to 15% of patients … [Read more]
From diagnosis to treatment, antisynthetase syndrome is attracting international attention
In France, the National Data Bank for Rare Diseases lists 1,156 patients followed up in Centres of Reference or Competence for an anti-synthetase syndrome (SAS), an entity associated with overlapping myositis, which until now has lacked a consensual definition. The members of the international project Classification Criteria for Anti-synthetase Syndrome (Class) : have identified clinical … [Read more]
